August 24, 2020 09:11 AM EDT

Which big biopharma player should gamble $34B on a ripe rare-disease M&A target? An action-hungry top analyst fills in the blanks

Geoffrey Porges has been openly unhappy with Ludwig Hantson and the team that runs Alexion $ALXN. Their discount M&A deals don’t make much sense …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Which big bio­phar­ma play­er should gam­ble $34B on a ripe rare-dis­ease M&A tar­get? An ac­tion-hun­gry top an­a­lyst fills in the blanks